Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands
Bart Slob, Tanja Fens, Maaike Weersma, Maarten Postma, Cornelis Boersma, Lisa de Jong, Larry Allan Weinrauch, Larry Allan Weinrauch, Larry Allan Weinrauch · 2024
Read Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands by Bart Slob, Tanja Fens, Maaike Weersma, Maarten Postma, Cornelis Boersma, Lisa de Jong, Larry Allan Weinrauch, Larry Allan Weinrauch, Larry Allan Weinrauch (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11630597.txt.
Description
Slob and colleagues published in twenty twenty-four a cost study of a kidney drug in the Netherlands. The drug empagliflozin slowed chronic kidney disease in a large recent trial. Whether it is worth its price in Dutch care was unknown. The team built a simulation that follows patients through kidney disease stages. It compared standard care alone with standard care plus the drug. Inputs came from the trial, national cost data, and published sources.
Adding the drug saved money overall in their model. Patients also gained more than a year of life on average. Quality-adjusted life years rose by a similar margin. Checks that varied the inputs kept the same conclusion. The authors call the drug a dominant option, meaning better and cheaper. The result held regardless of diabetes status.
Catalog record
| CREATOR | Bart Slob, Tanja Fens, Maaike Weersma, Maarten Postma, Cornelis Boersma, Lisa de Jong, Larry Allan Weinrauch, Larry Allan Weinrauch, Larry Allan Weinrauch |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |